Abstract
2212MO Major secondary outcomes in the multicentre noninferiority randomised trial IoN: Is ablative radioiodine necessary for low-risk differentiated thyroid cancer patients?
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have